After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
See which stocks are posting big moves after the bell.Market Insiderread more
"I'd love to say that the optimistic universe is most likely to prevail, but the talking heads talk endlessly about how a recession is inevitable," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Read the fine print in your Apple Card contract — one clause means you give up your right to be heard in court.Technologyread more
Federal Reserve members worried over future growth are highly concerned about the U.S.-China tariff battleThe Fedread more
President Donald Trump signed a memorandum on Wednesday to automatically cancel the student loan debt of disabled veterans. More than 25,000 service members will have their...Personal Financeread more
Jim Nussle, a former director of the Office of Management and Budget, told CNBC on Wednesday that a strong U.S. consumer is the only thing keeping the country from recession.Marketsread more
Eli Lilly plans to take a minority stake of its Elanco Animal Heath unit public, the pharmaceutical company said Tuesday.
Elanco's portfolio includes treatments for both livestock and pets.The decision comes after a strategic review of the business, which had weighed on Lilly's performance.
Lilly said it expects to offer a less than 20 percent stake in the new company in an initial public offering. Following the IPO, the company plans to divest its remaining ownership through a tax-efficient transaction.
Lilly share prices rose 4 percent Tuesday. At one point they were up nearly 6 percent, buoyed by the IPO plans and second-quarter earnings that were better than expected.
"Based on our strategic review, we concluded that after-tax value for Lilly shareholders would be maximized by pursuing an initial public offering of Elanco," Lilly CEO David Ricks said in a statement. "We believe this will allow Elanco to efficiently deploy its resources to those growth opportunities that best serve its customers. In addition, this will provide Lilly even greater focus on the human pharmaceutical business to pursue our purpose of creating life-changing medicines for patients."
Lilly expects to file a registration statement with the Securities and Exchange Commission in coming weeks and complete the IPO process in the second half of the year.
Correction: Eli Lilly plans to take public a less than 20 percent stake in its Elanco Animal Health unit. An earlier version incorrectly stated the company would hold a minority stake in the unit after the IPO.